Beta Bionics faces a securities class action filed in the U.S. District Court for the Central District of California on behalf of investors who purchased or otherwise acquired the company’s securities between July 30, 2025, and Feb. 24, 2026. The complaint alleges that Beta Bionics and its executives promoted the safety, efficacy and commercial success of iLet, the company’s sole commercialized device, while downplaying concerns raised in an October 2025 FDA Form 483. It alleges the company characterized the issues as involving complaint-reporting interpretations rather than iLet’s safety or efficacy, and said it did not foresee an ongoing challenge. The complaint further alleges that concerns emerged on Jan. 8, 2026, when Beta Bionics reported an unexpected shortfall in new iLet patient starts. Investors must move by Nov. 3, 2026, to seek appointment as lead plaintiff.